Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
877.79
-31.53 (-3.47%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
99
100
Next >
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
June 06, 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
June 06, 2024
The FDA's advisory committee will review Eli Lilly's Phase 3 study on donanemab for Alzheimer's disease on June 10. This review assesses the drug's benefit-risk profile based on significant efficacy...
Via
Benzinga
Exposures
Product Safety
Market Whales and Their Recent Bets on LLY Options
June 06, 2024
Via
Benzinga
Is Viking Therapeutics Stock a Buy on the Dip?
June 06, 2024
Short-term thinking is creating an intriguing opportunity for investors.
Via
The Motley Fool
Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half
June 06, 2024
Although going with the crowd comes with a certain comfort level, daring investors may want to consider these less-discussed momentum stocks.
Via
InvestorPlace
If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today
June 04, 2024
Via
Benzinga
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
June 03, 2024
Via
Benzinga
Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry
May 31, 2024
Via
Benzinga
Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition
June 06, 2024
Investors who want to put some sizzle in their portfolios should consider investing in these growth names that offer big returns.
Via
InvestorPlace
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
June 05, 2024
Via
Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....
Via
Benzinga
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
June 05, 2024
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment.
Via
Benzinga
Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO
June 05, 2024
Anat Ashkenazi resigns as CFO of Eli Lilly to join Google as CFO and SVP. She will remain at Lilly until July 2024 while her successor is sought.
Via
Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
June 05, 2024
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.
Via
Investor's Business Daily
Alphabet Picks Eli Lilly Executive Anat Ashkenazi As New CFO
June 05, 2024
Google stock rose after Alphabet announced that its new CFO will be Anat Ashkenazi, currently an executive at drug maker Eli Lilly.
Via
Investor's Business Daily
AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight
June 05, 2024
The valuation of Amazon stock is quite low while multiple, large investors bought significant amounts of the shares in Q1.
Via
InvestorPlace
Large Cap BIopharmaceuticals Overview
June 03, 2024
As a defensive play healthcare is weighted at about 12% of the S&P 500.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
June 03, 2024
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
Via
Benzinga
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
June 03, 2024
QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with...
Via
Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
June 03, 2024
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
June 03, 2024
Via
Benzinga
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
June 03, 2024
The fight for dominance in the weight loss market is just getting started.
Via
The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
June 03, 2024
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments
Via
MarketBeat
4 Stocks Making New Highs Despite Market Weakness
June 03, 2024
While the market faced challenges on Friday, Birkenstock, NetApp, Eli Lilly, and Aflac showed notable strength by achieving new 52-week highs.
Via
MarketBeat
The Week Ahead: What's Next
June 02, 2024
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.
Via
Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
June 02, 2024
These two drugmakers have a lot more in common than their market-beating potential.
Via
The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
June 01, 2024
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs.
Via
The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
June 01, 2024
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
May 31, 2024
Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure or falsely labeled semaglutide products.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
May 31, 2024
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider.
Via
InvestorPlace
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.